Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

CO-Promotion Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

CO-Promotion Agreement

Entities:

Santarus, Inc.; University of Missouri

Date:

2004

Size:

Preview shows 4KB of 117KB total

Price:

$53

ID:

#1047005

 

 

► Business ► Promotion ► Co-Promotion Agreements
► Miscellany ► Universities
► Biotech & Drugs ► Pharmaceutical Preparations

 

 

Start of Preview


FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.


CO-PROMOTION AGREEMENT

This CO-PROMOTION AGREEMENT (this "Agreement") is entered into and
effective as of this 4th day of October, 2004 (the "Effective Date"), by and
between SANTARUS, INC., a Delaware corporation ("Santarus"), and OTSUKA AMERICA
PHARMACEUTICAL, INC., a Delaware corporation ("Co-Promotion Partner").

WHEREAS, Santarus has exclusive rights to market and distribute the
Products in the United States;

WHEREAS, Co-Promotion Partner is engaged in the business of and has
expertise in, among other things, the promotion of pharmaceutical products; and

WHEREAS, Santarus and Co-Promotion Partner desire to work together to
promote the Products in the United States upon the terms and conditions set
forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth in this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

1. Definitions. Capitalized terms used herein without definition shall
have the meanings specified in this Section 1 (such definitions to be equally
applicable to both the singular and plural forms of the terms defined). Unless
otherwise specified, all references in this Agreement to "Sections" are to
Sections of this Agreement.

"Act" shall mean the United States Federal Food, Drug, and Cosmetic
Act, as it may be amended from time to time.

"Affiliate" shall mean, with respect to any Person, any other Person
that directly, or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with, such Person. A Person shall be
regarded as in control of another Person if such Person owns, or directly or
indirectly controls, more than fifty percent (50%) of the voting securities (or
comparable equity interests) or other ownership interests of the other Person,
or if such Person directly or indirectly possesses the power to direct or cause
the direction of the management or policies of the other Person, whether through
the ownership of voting securities, by contract or any other means whatsoever.

"Agreement" shall mean this Agreement, as the same may be amended or
supplemented from time to time hereafter pursuant to the provisions hereof.

"Commercially Reasonable Efforts" shall mean efforts and resources
commonly used in the pharmaceutical industry by similarly situated companies for
a product, which is of similar market potential at a similar stage in its
product life, taking into account issues of safety, efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved, the profitability of the applicable product,
and other relevant commercial factors.

"Contract Year" shall mean a 12-month period commencing as of a date
certain and ending 12-months later.

<PAGE>

"Co-Promotion Partner Trademarks" shall mean the trademark "Otsuka
America Pharmaceutical, Inc.," "OAPI" and any other related trademark or service
mark (whether registered or unregistered) containing the word "Otsuka.

"Co-Promotion Partner Target Healthcare Professionals" shall mean those
primary care physicians (i.e., general practitioners, family practitioners and
internal medicine physicians), gastroenterologists and other prescribers (i.e.,
nurse practitioners and physician assistants) identified in the Marketing Plans,
in each case who are authorized by applicable law to prescribe the Products.

"Detailing Costs" shall mean all costs which are directly related to
the establishment, maintenance, training and functioning of either party's sales
force, including, without limitation, [***].

"FDA" shall mean the United States Food and Drug Administration or any
successor entity thereto.

 

End of Preview

 

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC